Advance in angiogenesis inhibitors in the treatment of non-small cell lung cancer / 中国医师杂志
Journal of Chinese Physician
;
(12): 959-960,封3, 2017.
Artigo
em Chinês
| WPRIM
| ID: wpr-620901
ABSTRACT
Angiogenesis is vital in the process of primary tumor growth,proliferation and metastasis.In many cancers,including non-small cell lung cancer (NSCLC),inhibition of tumor angiogenesis has been identified as an important therapy.The most common drugs include bevacizumab,ramucirumab,tyrosine kinase inhibitor such as sorafenib tosylate,and nintedanib.We will summarize the research about some inhibition of tumor angiogenesis.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Journal of Chinese Physician
Ano de publicação:
2017
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS